SCHEMBL4883039

SCHEMBL4883039

Fc1ccc(-c2cc3ccccc3n2-c2ccccc2)cc1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HAO1 Q9UJM8 1/20 0.49
APP P05067 2/20 0.47
ALDH1A1 P00352 4/20 0.46
TSHR P16473 2/20 0.46
KMT2A Q03164 2/20 0.46
CYP19A1 P11511 2/20 0.43
PTGS2 P35354 2/20 0.42
ALOX5 P09917 1/20 0.42
GRIA1 P42261 1/20 0.41
CACNG8 Q8WXS5 1/20 0.41
CACNG2 Q9Y698 1/20 0.41
KDM4E B2RXH2 2/20 0.41
MEN1 O00255 1/20 0.41
NPC1 O15118 1/20 0.41
MAPT P10636 1/20 0.41
RAB9A P51151 1/20 0.41
L3MBTL1 Q9Y468 1/20 0.40
NR3C1 P04150 1/20 0.39
HPGD P15428 1/20 0.38
HSD17B10 Q99714 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4886994 0.93 HAO1 (0.56) HAO1APPALDH1A1TSHRKMT2A
SCHEMBL1878805 0.88 HAO1 (0.58) HAO1APPALDH1A1TSHRKMT2A
SCHEMBL14644724 0.87 NR3C1 (0.43) HAO1APPTSHRKMT2APTGS2
SCHEMBL14644368 0.87 NR3C1 (0.50) HAO1APPTSHRKMT2APTGS2
SCHEMBL14643973 0.86 NR3C1 (0.46) HAO1APPTSHRKMT2APTGS2
SCHEMBL14644711 0.86 NR3C1 (0.52) HAO1APPTSHRKMT2APTGS2
SCHEMBL14644410 0.85 NR3C1 (0.46) HAO1APPTSHRKMT2APTGS2
SCHEMBL3867353 0.84 HAO1 (0.59) HAO1APPALDH1A1TSHRKMT2A
SCHEMBL14644746 0.84 NR3C1 (0.48) HAO1APPTSHRKMT2ACYP19A1
SCHEMBL13425022 0.84 HAO1 (0.62) HAO1APPALDH1A1TSHRKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080039625-A1 Screening Methods LAUTENS MARK 2008-02-14 US disclosed
US-20080039625-A1 Screening Methods LAUTENS MARK 2008-02-14 US disclosed
US-20080039625-A1 Screening Methods LAUTENS MARK 2008-02-14 US disclosed
EP-1817283-A1 2-SUBSTITUTED INDOLES, THEIR PRECURSORS AND NOVEL PROCESSES FOR THE PREPARATION THEREOF Lautens, Mark (CA) 2007-08-15 EP disclosed
WO-2006047888-A1 2-SUBSTITUTED INDOLES, THEIR PRECURSORS AND NOVEL PROCESSES FOR THE PREPARATION THEREOF LAUTENS MARK (CA) 2006-05-11 WO disclosed
US-5374701-A Crosslinkable polymers of high strength free of structural defects HAY ALLAN S (CA) 1994-12-20 US disclosed
US-5233046-A DIARYLACETYLENES, ENAMINES AND ACETYLENIC POLYMERS AND THEIR PRODUCTION HAY ALLAN S (CA) 1993-08-03 US disclosed
WO-1993009079-A1 DIARYLACETYLENES, ENAMINES AND ACETYLENIC POLYMERS AND THEIR PRODUCTION HAY ALAN S (CA) 1993-05-13 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080039625-A1 Screening Methods CBR3, ZKSCAN2, CRBN HAO1 904/4885APP 4604/4885ALDH1A1 2175/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.